{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:33:36Z","timestamp":1750941216839,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R006253\/1"],"award-info":[{"award-number":["MR\/R006253\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with non-severe ANCA-associated vasculitis (AAV) are often prescribed immunosuppressive medications that are associated with severe side effects and a reduced quality of life. There is an unmet need for safer effective treatments for these patients. Hydroxychloroquine is being explored due to its effect in similar autoimmune conditions such as systemic lupus erythematosus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Double-blind, placebo-controlled multicentre trial recruiting 76 patients across 20 sites. Participants will be randomised 1:1 to hydroxychloroquine or placebo in addition to standard of care immunosuppressive therapies over the course of 52 weeks. A phase II selection design will be used to determine hdroxychloroquine\u2019s efficacy, using prednisolone dosage and Birmingham Vasculitis Activity Score as a measure of disease activity. Secondary outcomes will explore other elements of AAV progression, including disease flares and time to remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial aims to explore Hydroxychloroquine as a treatment for patients with AAV. If effective, the need for immunosuppressive treatments such as prednisolone could be reduced. Hydroxychloroquine is safer, cheaper and has fewer adverse effects than conventional immunosuppressive treatments. This could improve patient outcomes while saving money for the NHS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN: ISRCTN79334891. Registered 07 June 2021.<\/jats:p>\n                <jats:p>EudraCT: 2018-001268-40. Registered 13 September 2019.<\/jats:p>\n                <jats:p>Clinicaltrials.gov: NCT04316494. Registered 20 March 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07108-3","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T11:04:44Z","timestamp":1680779084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The HAVEN study\u2014hydroxychloroquine in ANCA vasculitis evaluation\u2014a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6964-9041","authenticated-orcid":false,"given":"Annastazia E.","family":"Learoyd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Beckley-Hoelscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Casian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish","family":"Sangle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Cape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangmi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharshene","family":"Shivapatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raashid","family":"Luqmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel","family":"Douiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"D\u2019Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the HAVEN study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"7108_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/s-2004-836139","volume":"25","author":"RA Watts","year":"2004","unstructured":"Watts RA, Scott DGI. Epidemiology of the vasculitides. Semin Respir Crit Care Med. 2004;25:455\u201364.","journal-title":"Semin Respir Crit Care Med"},{"key":"7108_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, De Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488\u201394.","journal-title":"Ann Rheum Dis"},{"key":"7108_CR3","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790\u2013803.","journal-title":"N Engl J Med"},{"key":"7108_CR4","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/1529-0131(199812)41:12<2257::AID-ART22>3.0.CO;2-K","volume":"41","author":"GS Hoffman","year":"1998","unstructured":"Hoffman GS, Drucker Y, Cotch MF, et al. Wegener\u2019s granulomatoisis: patient-reported effects of disease on health, function, and income. Arthritis Rheum. 1998;41:2257\u201362.","journal-title":"Arthritis Rheum"},{"key":"7108_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","volume":"142","author":"PA Merkel","year":"2005","unstructured":"Merkel PA, Lo GH, Holbrook JT, et al. Brief Communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis: The Wegener\u2019s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142:620.","journal-title":"Ann Intern Med"},{"key":"7108_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.20433","volume":"63","author":"R Suppiah","year":"2011","unstructured":"Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener\u2019s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588\u201396.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7108_CR7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody\u2013associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62:1166\u201373.","journal-title":"Arthritis Care Res"},{"key":"7108_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJM199101173240303","volume":"324","author":"The Canadian Hydroxychloroquine Study Group","year":"1991","unstructured":"The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150\u20134.","journal-title":"N Engl J Med"},{"key":"7108_CR9","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1177\/0961203396005001051","volume":"5","author":"M Petri","year":"1996","unstructured":"Petri M. Hydroxychloroquine use in the baltimore lupus cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5:S16\u201322.","journal-title":"Lupus"},{"key":"7108_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/BOR.0000000000000126","volume":"27","author":"A Makol","year":"2015","unstructured":"Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015;27:63\u201370.","journal-title":"Curr Opin Rheumatol"},{"key":"7108_CR11","first-page":"229","volume":"11","author":"G Mumcu","year":"2013","unstructured":"Mumcu G, Bi\u00e7ak\u00e7igil M, Yilmaz N, et al. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sj\u00f6gren\u2019s syndrome. Oral Heal Prev Dent. 2013;11:229\u201334.","journal-title":"Oral Heal Prev Dent"},{"key":"7108_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/art.38956","volume":"67","author":"M Jachiet","year":"2015","unstructured":"Jachiet M, Flageul B, Deroux A, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheum. 2015;67:527\u201334.","journal-title":"Arthritis Rheum"},{"key":"7108_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/annrheumdis-2016-eular.5464","volume":"75","author":"A Casian","year":"2016","unstructured":"Casian A, Sangle S, D\u2019Cruz D. The role of hydroxychloroquine in anti-neutrophil cytoplasmic antibody\u2013positive and negative vasculitis. Ann Rheum Dis. 2016;75:1086\u20137.","journal-title":"Ann Rheum Dis"},{"key":"7108_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1196\/annals.1422.003","volume":"1108","author":"A Tanay","year":"2007","unstructured":"Tanay A, Leibovitz E, Frayman A, et al. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad Sci. 2007;1108:24\u201334.","journal-title":"Ann N Y Acad Sci"},{"key":"7108_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","volume":"30","author":"JM Rolain","year":"2007","unstructured":"Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30:297\u2013308.","journal-title":"Int J Antimicrob Agents"},{"key":"7108_CR16","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/art.39070","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 2015;67:1577\u201385.","journal-title":"Arthritis Rheum"},{"key":"7108_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577\u201383.","journal-title":"Lupus"},{"key":"7108_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1046\/j.1365-2141.2001.02553.x","volume":"112","author":"L Lagneaux","year":"2001","unstructured":"Lagneaux L, Delforge A, Carlier S, et al. Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. Br J Haematol. 2001;112:344\u201352.","journal-title":"Br J Haematol"},{"key":"7108_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/CAD.0b013e32832f4e50","volume":"20","author":"R Rahim","year":"2009","unstructured":"Rahim R, Strobl JS. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anti-Cancer Drugs. 2009;20:736\u201345.","journal-title":"Anti-Cancer Drugs"},{"key":"7108_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"key":"7108_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"7108_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771\u201380.","journal-title":"N Engl J Med"},{"key":"7108_CR23","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827\u201332.","journal-title":"Ann Rheum Dis"},{"key":"7108_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"A Exley","year":"1997","unstructured":"Exley A, Bacon P, Luqmani R, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371\u201380.","journal-title":"Arthritis Rheum"},{"key":"7108_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"16","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;16:79.","journal-title":"Health Qual Life Outcomes"},{"key":"7108_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JJ Ware","year":"1992","unstructured":"Ware JJ, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473\u201383.","journal-title":"Med Care"},{"key":"7108_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (New York). 1990;16:199\u2013208.","journal-title":"Health Policy (New York)"},{"key":"7108_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries J. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.","journal-title":"Health Qual Life Outcomes"},{"key":"7108_CR29","first-page":"1157","volume":"77","author":"JC Robson","year":"2018","unstructured":"Robson JC, Dawson J, Doll H, et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis Rhemautic Dis. 2018;77:1157\u201364.","journal-title":"Ann Rheum Dis Rhemautic Dis"},{"key":"7108_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","volume":"76","author":"EM Miloslavsky","year":"2017","unstructured":"Miloslavsky EM, Naden RP, Bijlsma J, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76:543\u20136.","journal-title":"Ann Rheum Dis"},{"key":"7108_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44:912\u201320.","journal-title":"Arthritis Rheum"},{"key":"7108_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2009","unstructured":"Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2009;349:36\u201344.","journal-title":"N Engl J Med"},{"key":"7108_CR33","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheum. 2005;52:2461\u20139.","journal-title":"Arthritis Rheum"},{"key":"7108_CR34","first-page":"1375","volume":"69","author":"R Simon","year":"1985","unstructured":"Simon R, Wittes R, Ellenberg S. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69:1375\u201381.","journal-title":"Cancer Treat Rep"},{"key":"7108_CR35","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","volume":"76","author":"JA Tan","year":"2017","unstructured":"Tan JA, Dehghan N, Chen W, et al. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017;76:1566\u201374.","journal-title":"Ann Rheum Dis"},{"key":"7108_CR36","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/rheumatology\/kez589","volume":"59","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Fu X, Harkness T, et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology. 2020;59:2308\u201315.","journal-title":"Rheumatology"},{"key":"7108_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/annrheumdis-2012-202750","volume":"73","author":"N Basu","year":"2014","unstructured":"Basu N, McClean A, Harper L, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis. 2014;73:207\u201311.","journal-title":"Ann Rheum Dis"},{"key":"7108_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.semarthrit.2017.08.005","volume":"47","author":"CT Thorpe","year":"2018","unstructured":"Thorpe CT, Thorpe JM, Jiang T, et al. Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis. Semin Arthritis Rheum. 2018;47:507\u201319.","journal-title":"Semin Arthritis Rheum"},{"key":"7108_CR39","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3899\/jrheum.150479","volume":"42","author":"K Raimundo","year":"2015","unstructured":"Raimundo K, Farr AM, Kim G, et al. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol. 2015;42:2383\u201391.","journal-title":"J Rheumatol"},{"key":"7108_CR40","first-page":"721","volume":"32","author":"W Mau","year":"2005","unstructured":"Mau W, Listing J, Huscher D, et al. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol. 2005;32:721\u20138.","journal-title":"J Rheumatol"},{"key":"7108_CR41","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622\u201331.","journal-title":"N Engl J Med"},{"key":"7108_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000368569","volume":"128","author":"V Tesar","year":"2014","unstructured":"Tesar V, Hruskova Z. Limitations of standard immunosuppressive treatment in ANCA-associated vasculitis and lupus nephritis. Nephron Clin Pr. 2014;128:205\u201315.","journal-title":"Nephron Clin Pr"},{"key":"7108_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00296-017-3855-6","volume":"38","author":"JC Robson","year":"2018","unstructured":"Robson JC, Dawson J, Cronholm PF, et al. Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol Int. 2018;38:675\u201382.","journal-title":"Rheumatol Int"},{"key":"7108_CR44","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"M Little","year":"2010","unstructured":"Little M, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69:1036\u201343.","journal-title":"Ann Rheum Dis"},{"key":"7108_CR45","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S2665-9913(20)30276-9","volume":"2","author":"JCE Lane","year":"2020","unstructured":"Lane JCE, Weaver J, Kostka K, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020;2:e698\u2013711.","journal-title":"Lancet Rheumatol"},{"key":"7108_CR46","doi-asserted-by":"publisher","first-page":"16887","DOI":"10.1161\/JAHA.120.016887","volume":"9","author":"TJ Kamp","year":"2020","unstructured":"Kamp TJ, Hamdan MH, January CT. Chloroquine or hydroxychloroquine for COVID-19: is cardiotoxicity a concern? J Am Heart Assoc. 2020;9:16887.","journal-title":"J Am Heart Assoc"},{"key":"7108_CR47","doi-asserted-by":"publisher","first-page":"e20044","DOI":"10.2196\/20044","volume":"22","author":"K Niburski","year":"2020","unstructured":"Niburski K, Niburski O. Impact of Trump\u2019s promotion of unproven COVID-19 treatments and subsequent Internet trends: observational study. J Med Internet Res. 2020;22:e20044.","journal-title":"J Med Internet Res"},{"key":"7108_CR48","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"The RECOVERY Collaborative Group","year":"2020","unstructured":"The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020;383:2030\u201340.","journal-title":"N Engl J Med"},{"key":"7108_CR49","doi-asserted-by":"publisher","first-page":"m2126","DOI":"10.1136\/bmj.m2126","volume":"369","author":"E Mahase","year":"2020","unstructured":"Mahase E. Covid-19: WHO halts hydroxychloroquine trial to review links with increased mortality risk. BMJ. 2020;369:m2126.","journal-title":"BMJ"},{"key":"7108_CR50","doi-asserted-by":"publisher","first-page":"102986","DOI":"10.1016\/j.autrev.2021.102986","volume":"20","author":"A Kronbichler","year":"2021","unstructured":"Kronbichler A, Geetha D, Smith RM, et al. The COVID-19 pandemic and ANCA-associated vasculitis \u2013 reports from the EUVAS meeting and EUVAS education forum. Autoimmun Rev. 2021;20:102986.","journal-title":"Autoimmun Rev"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07108-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07108-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07108-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T12:18:35Z","timestamp":1680783515000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07108-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7108"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07108-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial will adhere to the UK Framework for Health and Social Care research. Prior to participation, all subjects provide informed consent and are informed in advance that they can withdraw from the trial at any time without penalty.The trial was approved by the London \u2013 Riverside Research Ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DDC reports participating in a speaker bureau for Vifor Pharma.The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}